View in EDS

Mezigdomide combined with bortezomib disrupts the cell cycle and elicits superior antitumor effects in multiple myeloma.

Saved in:
Bibliographic Details
Title: Mezigdomide combined with bortezomib disrupts the cell cycle and elicits superior antitumor effects in multiple myeloma.
Authors: Bjorklund CC; Bristol Myers Squibb, Translational Development, Summit, NJ., Larrayoz M; Center for Applied Medical Research CIMA, Cancer Center University of Navarra, Navarra Institute for Health Research (IDISNA), Centro de Investigation Biomedica en Red (CIBERONC), Pamplona, Spain., Kang J; Bristol Myers Squibb, Translational Development, Summit, NJ., Chiu H; Bristol Myers Squibb, Translational Development, Summit, NJ., Shtraizent N; Bristol Myers Squibb, Translational Development, Summit, NJ., Wu L; Bristol Myers Squibb, Translational Development, Summit, NJ., Li S; Bristol Myers Squibb, Translational Development, Summit, NJ., Hsu CC; Bristol Myers Squibb, Translational Development, Summit, NJ., Zhao J; Bristol Myers Squibb, Translational Development, Summit, NJ., Amatangelo M; Bristol Myers Squibb, Translational Development, Summit, NJ., Chow TT; Bristol Myers Squibb, Translational Development, Summit, NJ., Wollerman K; Bristol Myers Squibb, Translational Development, Summit, NJ., Singh RK; Biocon Bristol Myers Squibb, Research and Development Centre, Syngene International Ltd, Bangalore, India., Sridhara S; Biocon Bristol Myers Squibb, Research and Development Centre, Syngene International Ltd, Bangalore, India., Dudhgaonkar S; Bristol Myers Squibb, Research and Development, Bangalore, India., Subramanyam P; Biocon Bristol Myers Squibb, Research and Development Centre, Syngene International Ltd, Bangalore, India., Ghosh K; Bristol Myers Squibb, Research and Development, Bangalore, India., Richardson PG; Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center, Boston, MA., Bahlis NJ; Arnie Charbonneau Cancer Institute, Cumming School of Medicine, Department of Oncology, University of Calgary, Calgary, AB, Canada., Thakurta A; Bristol Myers Squibb, Translational Development, Summit, NJ.; Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom., Martinez-Climent JA; Center for Applied Medical Research CIMA, Cancer Center University of Navarra, Navarra Institute for Health Research (IDISNA), Centro de Investigation Biomedica en Red (CIBERONC), Pamplona, Spain., Gandhi AK; Bristol Myers Squibb, Translational Development, Summit, NJ., Hagner PR; Bristol Myers Squibb, Translational Development, Summit, NJ.
Source: Blood neoplasia [Blood Neoplasia] 2025 Nov 07; Vol. 3 (1), pp. 100179. Date of Electronic Publication: 2025 Nov 07 (Print Publication: 2026).
Publication Type: Journal Article
Journal Info: Publisher: Elsevier, Inc Country of Publication: United States NLM ID: 9918841988906676 Publication Model: eCollection Cited Medium: Internet ISSN: 2950-3280 (Electronic) Linking ISSN: 29503280 NLM ISO Abbreviation: Blood Neoplasia Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41626055
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Mezigdomide combined with bortezomib disrupts the cell cycle and elicits superior antitumor effects in multiple myeloma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Bjorklund+CC%22">Bjorklund CC</searchLink>; Bristol Myers Squibb, Translational Development, Summit, NJ.<br /><searchLink fieldCode="AU" term="%22Larrayoz+M%22">Larrayoz M</searchLink>; Center for Applied Medical Research CIMA, Cancer Center University of Navarra, Navarra Institute for Health Research (IDISNA), Centro de Investigation Biomedica en Red (CIBERONC), Pamplona, Spain.<br /><searchLink fieldCode="AU" term="%22Kang+J%22">Kang J</searchLink>; Bristol Myers Squibb, Translational Development, Summit, NJ.<br /><searchLink fieldCode="AU" term="%22Chiu+H%22">Chiu H</searchLink>; Bristol Myers Squibb, Translational Development, Summit, NJ.<br /><searchLink fieldCode="AU" term="%22Shtraizent+N%22">Shtraizent N</searchLink>; Bristol Myers Squibb, Translational Development, Summit, NJ.<br /><searchLink fieldCode="AU" term="%22Wu+L%22">Wu L</searchLink>; Bristol Myers Squibb, Translational Development, Summit, NJ.<br /><searchLink fieldCode="AU" term="%22Li+S%22">Li S</searchLink>; Bristol Myers Squibb, Translational Development, Summit, NJ.<br /><searchLink fieldCode="AU" term="%22Hsu+CC%22">Hsu CC</searchLink>; Bristol Myers Squibb, Translational Development, Summit, NJ.<br /><searchLink fieldCode="AU" term="%22Zhao+J%22">Zhao J</searchLink>; Bristol Myers Squibb, Translational Development, Summit, NJ.<br /><searchLink fieldCode="AU" term="%22Amatangelo+M%22">Amatangelo M</searchLink>; Bristol Myers Squibb, Translational Development, Summit, NJ.<br /><searchLink fieldCode="AU" term="%22Chow+TT%22">Chow TT</searchLink>; Bristol Myers Squibb, Translational Development, Summit, NJ.<br /><searchLink fieldCode="AU" term="%22Wollerman+K%22">Wollerman K</searchLink>; Bristol Myers Squibb, Translational Development, Summit, NJ.<br /><searchLink fieldCode="AU" term="%22Singh+RK%22">Singh RK</searchLink>; Biocon Bristol Myers Squibb, Research and Development Centre, Syngene International Ltd, Bangalore, India.<br /><searchLink fieldCode="AU" term="%22Sridhara+S%22">Sridhara S</searchLink>; Biocon Bristol Myers Squibb, Research and Development Centre, Syngene International Ltd, Bangalore, India.<br /><searchLink fieldCode="AU" term="%22Dudhgaonkar+S%22">Dudhgaonkar S</searchLink>; Bristol Myers Squibb, Research and Development, Bangalore, India.<br /><searchLink fieldCode="AU" term="%22Subramanyam+P%22">Subramanyam P</searchLink>; Biocon Bristol Myers Squibb, Research and Development Centre, Syngene International Ltd, Bangalore, India.<br /><searchLink fieldCode="AU" term="%22Ghosh+K%22">Ghosh K</searchLink>; Bristol Myers Squibb, Research and Development, Bangalore, India.<br /><searchLink fieldCode="AU" term="%22Richardson+PG%22">Richardson PG</searchLink>; Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Bahlis+NJ%22">Bahlis NJ</searchLink>; Arnie Charbonneau Cancer Institute, Cumming School of Medicine, Department of Oncology, University of Calgary, Calgary, AB, Canada.<br /><searchLink fieldCode="AU" term="%22Thakurta+A%22">Thakurta A</searchLink>; Bristol Myers Squibb, Translational Development, Summit, NJ.; Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Martinez-Climent+JA%22">Martinez-Climent JA</searchLink>; Center for Applied Medical Research CIMA, Cancer Center University of Navarra, Navarra Institute for Health Research (IDISNA), Centro de Investigation Biomedica en Red (CIBERONC), Pamplona, Spain.<br /><searchLink fieldCode="AU" term="%22Gandhi+AK%22">Gandhi AK</searchLink>; Bristol Myers Squibb, Translational Development, Summit, NJ.<br /><searchLink fieldCode="AU" term="%22Hagner+PR%22">Hagner PR</searchLink>; Bristol Myers Squibb, Translational Development, Summit, NJ.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229918841988906676%22">Blood neoplasia</searchLink> [Blood Neoplasia] 2025 Nov 07; Vol. 3 (1), pp. 100179. <i>Date of Electronic Publication: </i>2025 Nov 07 (<i>Print Publication: </i>2026).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%2C+Inc%22">Elsevier, Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9918841988906676 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2950-3280 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2229503280%22">29503280 </searchLink><i>NLM ISO Abbreviation: </i>Blood Neoplasia <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41626055
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.bneo.2025.100179
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 100179
    Titles:
      – TitleFull: Mezigdomide combined with bortezomib disrupts the cell cycle and elicits superior antitumor effects in multiple myeloma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Bjorklund CC
      – PersonEntity:
          Name:
            NameFull: Larrayoz M
      – PersonEntity:
          Name:
            NameFull: Kang J
      – PersonEntity:
          Name:
            NameFull: Chiu H
      – PersonEntity:
          Name:
            NameFull: Shtraizent N
      – PersonEntity:
          Name:
            NameFull: Wu L
      – PersonEntity:
          Name:
            NameFull: Li S
      – PersonEntity:
          Name:
            NameFull: Hsu CC
      – PersonEntity:
          Name:
            NameFull: Zhao J
      – PersonEntity:
          Name:
            NameFull: Amatangelo M
      – PersonEntity:
          Name:
            NameFull: Chow TT
      – PersonEntity:
          Name:
            NameFull: Wollerman K
      – PersonEntity:
          Name:
            NameFull: Singh RK
      – PersonEntity:
          Name:
            NameFull: Sridhara S
      – PersonEntity:
          Name:
            NameFull: Dudhgaonkar S
      – PersonEntity:
          Name:
            NameFull: Subramanyam P
      – PersonEntity:
          Name:
            NameFull: Ghosh K
      – PersonEntity:
          Name:
            NameFull: Richardson PG
      – PersonEntity:
          Name:
            NameFull: Bahlis NJ
      – PersonEntity:
          Name:
            NameFull: Thakurta A
      – PersonEntity:
          Name:
            NameFull: Martinez-Climent JA
      – PersonEntity:
          Name:
            NameFull: Gandhi AK
      – PersonEntity:
          Name:
            NameFull: Hagner PR
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 07
              M: 11
              Text: 2025 Nov 07
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2950-3280
          Numbering:
            – Type: volume
              Value: 3
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Blood neoplasia
              Type: main
ResultId 1